Calmare Therapeutics (CTTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 01-2009 | 10-2008 | 07-2008 | 04-2008 | 01-2008 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 694 | 1,146 | 2,237 | 2,901 | 4,522 |
| Receivables | 289 | 252 | 120 | 948 | 680 |
| Inventories | N/A | N/A | N/A | 31 | 34 |
| TOTAL | $1,143 | $1,645 | $2,675 | $4,050 | $5,430 |
| Non-Current Assets | |||||
| PPE Net | 232 | 248 | 263 | 281 | 290 |
| Other Non-Current Assets | 283 | 297 | 173 | 41 | 42 |
| TOTAL | $515 | $545 | $436 | $322 | $332 |
| Total Assets | $1,659 | $2,190 | $3,111 | $4,372 | $5,762 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 652 | 440 | 680 | 587 | 1,290 |
| Accrued Expenses | 616 | 774 | 759 | 1,071 | 800 |
| TOTAL | $1,268 | $1,214 | $1,439 | $1,658 | $2,090 |
| Non-Current Liabilities | |||||
| TOTAL | $81 | $80 | $79 | $75 | $71 |
| Total Liabilities | $1,348 | $1,294 | $1,518 | $1,733 | $2,161 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 8,787 | 8,453 | N/A | 8,180 | 8,180 |
| Common Shares | 86 | 83 | 82 | 82 | 82 |
| Retained earnings | -36,182 | -35,250 | -34,282 | -33,185 | -32,174 |
| TOTAL | $310 | $896 | $1,593 | $2,639 | $3,600 |
| Total Liabilities And Equity | $1,658 | $2,190 | $3,111 | $4,372 | $5,762 |